| Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) (NCT06660420) | M.D. Anderson Cancer Center | 2025-02-25 |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer (NCT06369259) | M.D. Anderson Cancer Center | 2025-02-24 |
| A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study (NCT06630091) | M.D. Anderson Cancer Center | 2025-02-21 |
| Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry (NCT06840288) | M.D. Anderson Cancer Center | 2025-02-19 |
| Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHASE (NCT06991062) | M.D. Anderson Cancer Center | 2025-02-19 |
| A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias (NCT06466395) | M.D. Anderson Cancer Center | 2025-02-18 |
| Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems (NCT06843720) | M.D. Anderson Cancer Center | 2025-02-17 |
| EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active (NCT06649058) | M.D. Anderson Cancer Center | 2025-02-14 |
| Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE) (NCT06494111) | M.D. Anderson Cancer Center | 2025-02-13 |
| Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (NCT06445907) | M.D. Anderson Cancer Center | 2025-02-12 |
| The Effect of the Prostate Cancer Foundation Screening Guidelines for Black Men on Intention to Screen in Faith-based Communities (NCT06838325) | M.D. Anderson Cancer Center | 2025-02-06 |
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms (NCT06284460) | M.D. Anderson Cancer Center | 2025-01-31 |
| A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma (NCT06672575) | M.D. Anderson Cancer Center | 2025-01-30 |
| A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) (NCT06616636) | M.D. Anderson Cancer Center | 2025-01-30 |
| A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm (NCT06597734) | M.D. Anderson Cancer Center | 2025-01-28 |
| CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers (NCT06548412) | M.D. Anderson Cancer Center | 2025-01-22 |
| Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life (NCT06667427) | M.D. Anderson Cancer Center | 2025-01-13 |
| Impact of Diaphragmatic Breathing Coaching on Deep Inspiration Breath Hold Reproducibility and Organ Protection (NCT06747533) | M.D. Anderson Cancer Center | 2025-01-08 |
| Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain (NCT06287515) | M.D. Anderson Cancer Center | 2025-01-06 |
| A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies (NCT06668584) | M.D. Anderson Cancer Center | 2024-12-31 |
| ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial (NCT06664879) | M.D. Anderson Cancer Center | 2024-12-30 |
| A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias (NCT06397027) | M.D. Anderson Cancer Center | 2024-12-27 |
| A Randomized Controlled Trial to Assess the Impact of Live and Recorded Music-Based Interventions on Pre-operative Stress, Mood, Pain and Biomarkers, in Neurosurgical Patients (Music-STAR Trial) (NCT06536504) | M.D. Anderson Cancer Center | 2024-12-19 |
| ACT-Together (Acting on Cancer Testing-Together) (NCT06549153) | M.D. Anderson Cancer Center | 2024-12-18 |
| A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer (NCT06693687) | M.D. Anderson Cancer Center | 2024-12-18 |
| Symptom Burden and Health Related Quality of Life of Cancer Patients With Concurrent Heart Failure (NCT06656715) | M.D. Anderson Cancer Center | 2024-12-16 |
| Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer (NCT06743308) | M.D. Anderson Cancer Center | 2024-12-16 |
| Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell (NCT06575374) | M.D. Anderson Cancer Center | 2024-12-12 |
| A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma (NCT06563505) | M.D. Anderson Cancer Center | 2024-12-11 |
| Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) (NCT06522360) | M.D. Anderson Cancer Center | 2024-12-11 |
| Intelligent Optical Probe for Guiding Core Needle Biopsy Procedures (NCT06199492) | M.D. Anderson Cancer Center | 2024-12-05 |
| Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment. (NCT06507878) | M.D. Anderson Cancer Center | 2024-12-05 |
| Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (NCT06617858) | M.D. Anderson Cancer Center | 2024-12-04 |
| Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) (NCT06358430) | M.D. Anderson Cancer Center | 2024-12-02 |
| Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma (NCT06567314) | M.D. Anderson Cancer Center | 2024-12-02 |
| AIM4 AI and Mechanistic Modeling in Molecular Medicine (NCT06535828) | M.D. Anderson Cancer Center | 2024-11-30 |
| A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy (NCT06085625) | M.D. Anderson Cancer Center | 2024-11-26 |
| Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study (NCT05879146) | M.D. Anderson Cancer Center | 2024-11-26 |
| Communicating Health Options to Inform Care and Empower Strategic Care Planning (CHOICES): A Multi-layer Randomized Case Vignette Study. (NCT06722846) | M.D. Anderson Cancer Center | 2024-11-21 |
| A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors (NCT06598371) | M.D. Anderson Cancer Center | 2024-11-21 |
| Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study (NCT06639594) | M.D. Anderson Cancer Center | 2024-11-21 |
| Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma (NCT06448026) | M.D. Anderson Cancer Center | 2024-11-21 |
| The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients (NCT06639854) | M.D. Anderson Cancer Center | 2024-11-20 |
| Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion (NCT06439485) | M.D. Anderson Cancer Center | 2024-11-19 |
| Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery (NCT06204315) | M.D. Anderson Cancer Center | 2024-11-11 |
| A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma (NCT06308575) | M.D. Anderson Cancer Center | 2024-11-01 |
| Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin (NCT06576037) | M.D. Anderson Cancer Center | 2024-10-31 |
| Clinical and Molecular Features of Oral Premalignancy and Oral Cancer (NCT06550050) | M.D. Anderson Cancer Center | 2024-10-31 |
| Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial (NCT06593431) | M.D. Anderson Cancer Center | 2024-10-23 |
| Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease (NCT06522373) | M.D. Anderson Cancer Center | 2024-10-21 |
| Comparison of Conspicuity of Masses and Architectural Distortions Between Wide- and Narrow-angle Digital Breast Tomosynthesis Systems (NCT06373354) | M.D. Anderson Cancer Center | 2024-10-18 |
| Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) (NCT06545682) | M.D. Anderson Cancer Center | 2024-10-15 |
| Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) (NCT06434350) | M.D. Anderson Cancer Center | 2024-10-10 |
| Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies (NCT06444880) | M.D. Anderson Cancer Center | 2024-10-09 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (NCT06345495) | M.D. Anderson Cancer Center | 2024-10-01 |
| Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis (NCT06365918) | M.D. Anderson Cancer Center | 2024-09-30 |
| Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial. (NCT06989099) | M.D. Anderson Cancer Center | 2024-09-24 |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (NCT06284486) | M.D. Anderson Cancer Center | 2024-09-23 |
| Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED (NCT06548789) | M.D. Anderson Cancer Center | 2024-09-16 |
| A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis (NCT06619522) | M.D. Anderson Cancer Center | 2024-09-11 |
| A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy (NCT06647134) | M.D. Anderson Cancer Center | 2024-09-11 |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. (NCT06274047) | M.D. Anderson Cancer Center | 2024-09-10 |
| 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer (NCT06414902) | M.D. Anderson Cancer Center | 2024-09-04 |
| Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord (NCT06548776) | M.D. Anderson Cancer Center | 2024-09-04 |
| Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma (NCT06466434) | M.D. Anderson Cancer Center | 2024-09-01 |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations (NCT06412198) | M.D. Anderson Cancer Center | 2024-08-28 |
| Harmony & Health: A Culturally Adapted Mindbody Intervention to Reduce Sitting Time and Improve Psychosocial Wellbeing in Black Adults (NCT05922943) | M.D. Anderson Cancer Center | 2024-08-14 |
| Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment (NCT05041140) | M.D. Anderson Cancer Center | 2024-08-14 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions (NCT06308419) | M.D. Anderson Cancer Center | 2024-08-14 |
| Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) (NCT06408168) | M.D. Anderson Cancer Center | 2024-08-08 |
| A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia (NCT06401603) | M.D. Anderson Cancer Center | 2024-08-06 |
| Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT06308588) | M.D. Anderson Cancer Center | 2024-08-05 |
| Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) (NCT06327100) | M.D. Anderson Cancer Center | 2024-08-01 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders (NCT06434363) | M.D. Anderson Cancer Center | 2024-07-31 |
| Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV) (NCT06434337) | M.D. Anderson Cancer Center | 2024-07-23 |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (NCT06207799) | M.D. Anderson Cancer Center | 2024-07-17 |
| Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy (NCT06389721) | M.D. Anderson Cancer Center | 2024-07-16 |
| Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic (NCT06329531) | M.D. Anderson Cancer Center | 2024-07-12 |
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab (NCT06287229) | M.D. Anderson Cancer Center | 2024-07-11 |
| Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA) (NCT06377527) | M.D. Anderson Cancer Center | 2024-07-10 |
| Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy (NCT06569368) | M.D. Anderson Cancer Center | 2024-07-10 |
| A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia (NCT06285825) | M.D. Anderson Cancer Center | 2024-07-05 |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation (NCT06297629) | M.D. Anderson Cancer Center | 2024-07-01 |
| PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. (NCT06369246) | M.D. Anderson Cancer Center | 2024-06-27 |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies (NCT06383572) | M.D. Anderson Cancer Center | 2024-06-26 |
| Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women (NCT06409052) | M.D. Anderson Cancer Center | 2024-06-25 |
| Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder (NCT06261060) | M.D. Anderson Cancer Center | 2024-06-20 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer (NCT06083857) | M.D. Anderson Cancer Center | 2024-06-18 |
| Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. (NCT06087263) | M.D. Anderson Cancer Center | 2024-06-18 |
| Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health (NCT06431347) | M.D. Anderson Cancer Center | 2024-06-17 |
| Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (NCT06336642) | M.D. Anderson Cancer Center | 2024-06-11 |
| Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect (NCT06295783) | M.D. Anderson Cancer Center | 2024-06-10 |
| A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP) (NCT06367972) | M.D. Anderson Cancer Center | 2024-06-06 |
| Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies (NCT06199479) | M.D. Anderson Cancer Center | 2024-06-04 |
| A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes (NCT06229912) | M.D. Anderson Cancer Center | 2024-06-04 |
| Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation (NCT06450353) | M.D. Anderson Cancer Center | 2024-05-31 |
| Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer (NCT06318897) | M.D. Anderson Cancer Center | 2024-05-29 |
| Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients (NCT06263491) | M.D. Anderson Cancer Center | 2024-05-29 |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia (NCT06235801) | M.D. Anderson Cancer Center | 2024-05-22 |
| A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer (NCT06434402) | M.D. Anderson Cancer Center | 2024-05-22 |